人工智能增强的乳腺MRI:在乳腺癌原发系统治疗反应评估与预测中的应用
综述概述了人工智能(经典机器学习及深度学习)增强的乳腺MRI在原发系统治疗前及治疗早期预测乳腺癌治疗反应中的应用现状与前景,指出影像预测反应有助于预后判断、降阶或省略毒性治疗、加速新靶向治疗实施及减少手术延迟,并讨论了临床实施的挑战与局限。
要点
- 乳腺MRI是评估原发系统治疗反应的关键手段,但放射科医生定性主观评估预测反应能力有限。
- 人工智能增强MRI(经典机器学习及深度学习)在原发系统治疗前及治疗早期预测反应方面已显示有前景的结果。
- 影像预测反应有望改善预后判断、支持降阶或省略毒性治疗并加速新靶向治疗实施。
核心结论
- 人工智能增强的乳腺MRI在原发系统治疗前及治疗早期预测反应方面显示出有前景的结果,但临床实施仍面临挑战与局限。
研究设计与样本
- 综述,检索范围与纳入文献未在原文摘要中报告。
局限性
- 原文讨论了人工智能增强MRI临床实施的挑战与局限,但摘要未具体列出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Primary systemic therapy (PST) is the treatment of choice in patients with locally advanced breast cancer and is nowadays also often used in patients with early-stage breast cancer. Although imaging remains pivotal to assess response to PST accurately, the use of imaging to predict response to PST has the potential to not only better prognostication but also allow the de-escalation or omission of potentially toxic treatment with undesirable adverse effects, the accelerated implementation of new targeted therapies, and the mitigation of surgical delays in selected patients. In response to the limited ability of radiologists to predict response to PST via qualitative, subjective assessments of tumors on magnetic resonance imaging (MRI), artificial intelligence-enhanced MRI with classical machine learning, and in more recent times, deep learning, have been used with promising results to predict response, both before the start of PST and in the early stages of treatment. This review provides an overview of the current applications of artificial intelligence to MRI in assessing and predicting response to PST, and discusses the challenges and limitations of their clinical implementation.
引用
- Lo Gullo R, Marcus E, Huayanay J, et al. Artificial Intelligence-Enhanced Breast MRI: Applications in Breast Cancer Primary Treatment Response Assessment and Prediction. Invest Radiol. 2024. PMID: 37493391. doi:10.1097/RLI.0000000000001010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。